Literature DB >> 22801348

Rapid plasma reagin titer variation in the 2 weeks after syphilis therapy.

Katherine M Holman1, Mark Wolff, Arlene C Seña, David H Martin, Frieda Behets, Kathleen Van Damme, Peter Leone, Linda McNeil, Meredyth L Gehrig, Edward W Hook.   

Abstract

BACKGROUND: Serologic tests for syphilis results at the time of diagnosis are the basis for evaluating response to syphilis therapy. After treatment, however, serologic tests for syphilis titers may continue to increase for several weeks. We evaluated rapid plasma reagin (RPR) titer variation during the 14 days after therapy using data from a recent large, prospective randomized controlled trial.
METHODS: Prospectively enrolled participants in North America and Madagascar with primary, secondary, or early latent syphilis were randomly assigned to penicillin, doxycycline (in the case of penicillin allergy), or azithromycin treatment. Blood for RPR analysis was drawn at days 0, 7, and 14 posttreatment. All RPR titers were determined simultaneously at a central laboratory.
RESULTS: Four hundred and seventy patients had data available for at least 2 of 3 RPR measurements. Overall, 20% of patients showed a titer increase of at least 1 dilution in the 14 days after therapy. The greatest proportion of titer increases following therapy was observed in patients with primary syphilis. Comparing outcome of therapy using the initial (day 0) RPR titer versus the maximal RPR titer (during 14 days) resulted in outcome reclassification in 2.98% of participants.
CONCLUSIONS: Despite the fact that about 20% of early syphilis patients had increases in RPR titers immediately after treatment, these changes rarely influenced assessment of therapeutic outcome. Only 3% of patients treated would have been reclassified.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22801348      PMCID: PMC3399694          DOI: 10.1097/OLQ.0b013e3182536574

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  4 in total

1.  Characterization of the humoral immune response of the rabbit to antigens of Treponema pallidum after experimental infection and therapy.

Authors:  S A Lukehart; S A Baker-Zander; S Sell
Journal:  Sex Transm Dis       Date:  1986 Jan-Mar       Impact factor: 2.830

2.  Sexually transmitted diseases treatment guidelines, 2010.

Authors:  Kimberly A Workowski; Stuart Berman
Journal:  MMWR Recomm Rep       Date:  2010-12-17

3.  A phase III equivalence trial of azithromycin versus benzathine penicillin for treatment of early syphilis.

Authors:  Edward W Hook; Frieda Behets; Kathleen Van Damme; Noro Ravelomanana; Peter Leone; Arlene C Sena; David Martin; Carol Langley; Linda McNeil; Mark Wolff
Journal:  J Infect Dis       Date:  2010-06-01       Impact factor: 5.226

4.  Treatment of sexually transmitted infections for HIV prevention: end of the road or new beginning?

Authors:  Richard Hayes; Deborah Watson-Jones; Connie Celum; Janneke van de Wijgert; Judith Wasserheit
Journal:  AIDS       Date:  2010-10       Impact factor: 4.177

  4 in total
  4 in total

1.  A nodular-ulcerative form of secondary syphilis in AIDS.

Authors:  Ofelya Gevorgyan; Benjamin D Owen; Arvind Balavenkataraman; Mitchell R Weinstein
Journal:  Proc (Bayl Univ Med Cent)       Date:  2017-01

2.  Brazilian Protocol for Sexually Transmitted Infections 2020: syphilis diagnostic tests.

Authors:  Pâmela Cristina Gaspar; Álisson Bigolin; José Boullosa Alonso Neto; Esdras Daniel Dos Santos Pereira; Maria Luiza Bazzo
Journal:  Rev Soc Bras Med Trop       Date:  2021-05-17       Impact factor: 1.581

Review 3.  Current Perspectives on Prevention of Mother-to-Child Transmission of Syphilis.

Authors:  Eleonor G Lago
Journal:  Cureus       Date:  2016-03-09

4.  Serologic Response to Treatment in Human Immunodeficiency Virus-Negative Syphilis Patients Using Automated Serological Tests: Proposals for New Guidelines.

Authors:  Jung-In Kim; Ji-Hye Park; Ju-Yeon Choi; Ga-Young Lee; Won-Serk Kim
Journal:  Ann Dermatol       Date:  2017-10-30       Impact factor: 1.444

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.